A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene  by Prior, Thomas W. et al.
REPORT
A Positive Modifier of Spinal Muscular Atrophy
in the SMN2 Gene
Thomas W. Prior,1,4,* Adrian R. Krainer,2 Yimin Hua,2 Kathryn J. Swoboda,3 Pamela C. Snyder,1
Scott J. Bridgeman,1 Arthur H.M. Burghes,4,5 and John T. Kissel4
Spinal muscular atrophy (SMA) is a common autosomal-recessive motor neuron disease caused by the homozygous loss of the SMN1
gene. A nearly identical gene, SMN2, has been shown to decrease the severity of SMA in a dose-dependent manner. However SMN2 is
not the sole phenotypic modiﬁer, because there are discrepant SMA cases in which the SMN2 copy number does not explain the clinical
phenotype. This report describes three unrelated SMA patients who possessed SMN2 copy numbers that did not correlate with the
observed mild clinical phenotypes. A single base substitution in SMN2, c.859G>C,, was identiﬁed in exon 7 in the patients’ DNA.
We now show that the change creates a new exonic splicing enhancer element and increases the amount of full-length transcripts,
thus resulting in the less severe phenotypes. This demonstrates that the c.859G>C substitution is a positive modiﬁer of the SMA pheno-
type and that not all SMN2 genes are equivalent. We have shown not only that the SMA phenotype is modiﬁed by the number of SMN2
genes but that SMN2 sequence variations can also affect the disease severity.The autosomal-recessive disorder proximal spinal mus-
cular atrophy (SMA types I, II, and III [MIM 253300,
253550, and 253400]) is a severe neuromuscular disease
characterized by degeneration of alpha motor neurons in
the spinal cord, which results in progressive muscle weak-
ness and paralysis. SMA is the second most common fatal
autosomal-recessive disorder after cystic ﬁbrosis, with an
estimated prevalence of 1 in 10,000 live births.1 Childhood
SMA is subdivided into three clinical groups on the basis of
age of onset and clinical course.2,3 Type I SMA (Werdnig-
Hoffmann) is characterized by severe, generalized muscle
weakness and hypotonia at birth or within the ﬁrst three
months. Death from respiratory failure usually occurs
within the ﬁrst two years. Children with type II SMA are
able to sit, although they cannot stand or walk unaided,
and typically survive beyond four years. Type III SMA
(Kugelberg-Welander) is a milder form, with onset during
infancy or youth, and patients with type III SMA learn to
walk unaided and have prolonged survival rates. Type III
SMA is further subdivided into two groups: type IIIa (onset
before 3 years of age) and type IIIb (onset at ageR 3 years).
Patients presenting with the ﬁrst symptoms of the disease
at the age of 20–30 years are classiﬁed as type IV, or prox-
imal adult type SMA.
The survival motor neuron (SMN) gene (Entrez Gene ID
no. 6606) comprises nine exons and has been shown to be
the primary SMA-determining gene.4 Two almost identical
SMN genes are present on 5q13: the telomeric or SMN1
gene (MIM 600354), which is the SMA-determining gene,
and the centromeric or SMN2 gene (MIM 60127). The
SMN1 gene exon 7 is absent in about 95% of affected
patients, although small, more subtle mutations have
been identiﬁed in the remaining patients. Although muta-408 The American Journal of Human Genetics 85, 408–413, Septemtions of the SMN1 gene are observed in the majority of
patients, no phenotype-genotype correlation was initially
observed because SMN1 exon 7 is absent in the majority
of patients, independent of the type of SMA. This is due
to the fact that routine diagnostic methods do not distin-
guish between a deletion of SMN1 and a conversion event
whereby SMN1 is replaced by a copy of SMN2. Several
studies have shown that the SMN2 copy number modiﬁes
the severity of the disease.5–9 The copy number varies from
zero to three copies in the normal population, with
approximately 10%–15% of this population having no
SMN2. However, patients with the milder type II or III
SMA have been shown to have more copies of SMN2
than type I patients. The majority of patients with the
severe type I form have one or two copies of SMN2; most
patients with type II have three SMN2 copies; and most
patients with type III have three or four SMN2 copies.
Three unaffected family members of SMA patients with
conﬁrmed SMN1 deletions were shown to have ﬁve copies
of SMN2.10 This inverse dose relationship between SMN2
copy number and disease severity has also been supported
by the SMA mouse model.11,12 Mice lacking the endoge-
nous mouse Smn gene but expressing two copies of the
human SMN2 gene develop severe SMA and die within
one week of age. However, mice that express multiple
copies of SMN2 do not develop the disease.
The SMN1 gene produces a full-length transcript,
whereas the SMN2 gene produces predominantly an alter-
natively spliced transcript (exon 7 deleted) encoding a
protein (SMND7) that does not oligomerize efﬁciently
and is unstable.13,14 The inclusion of exon 7 in SMN1 tran-
scripts and exclusion of this exon in SMN2 transcripts is
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exon 7. Although the C-to-T change in SMN2 exon 7 does
not change an amino acid, it does disrupt an exonic
splicing enhancer (ESE) or creates an exon silencer element
(ESS), which results in the majority of transcripts lacking
exon 7.14,15 Therefore, SMA arises because the SMN2
gene cannot fully compensate for the lack of functional
SMN when SMN1 is mutated. However, a small amount
of full-length transcript generated by SMN2 accounts for
a milder type II or III phenotype when the copy number
of the SMN2 gene is increased.
In addition to the SMN2 copy number, other modifying
factors inﬂuence the phenotypic variability of SMA. There
are very rare reports of families in which markedly dif-
ferent degrees of disease severity are present in affected
siblings with the same SMN2 copy number. Differences
in splicing factors may allow more full-length expression
from the SMN2 gene and account for some of the vari-
ability observed between discordant siblings.16 It was also
found that in some rare families with unaffected SMN1-
deleted females, the expression of plastin 3 (PLS3, T-plastin
or T-ﬁmbrin [MIM 300131]) was higher than in their SMA-
affected counterparts.17 PLS3 was shown to be important
for axonogenesis and therefore may act as a protective
modiﬁer. The identiﬁcation of such gene modiﬁers not
only provides important insight into pathogenesis of
SMA but may also identify potential targets for therapy.
Several drugs have been shown to increase SMN2 expres-
sion in SMA patient-derived cell lines and are being studied
in ongoing clinical trials.18–20
Although the existence of discordant phenotypes within
a family and asymptomatic carriers with less than ﬁve
copies of SMN2 implies that additional genes are inﬂu-
encing the severity of SMA, another source of phenotypic
variationmay actually be due to the differential expression
of the SMN2 gene. It has generally been assumed that all
SMN2 genes are equivalent. We now present three cases
that clearly indicate that a single base change in the
SMN2 gene increases the amount of full-length transcripts
generated and positively modiﬁes the disease phenotype.
The affected case 1 individual is a 42-year-old patient
with type IIIb SMA who had normal early motor mile-
stones but walked on her toes for as long as she could
remember. She participated normally in activities while
in grade school but recalled always being slow, and she
often had to use a hand assist while going up and down
steps. By high school she noticed slight weakness in her
hips, but this was thought by her physician to be a normal
variation. Her disease declared itself in her early 20s, when
her husband witnessed her fall and became convinced that
her leg strength was not normal. She sought neurologic
consultation, and a DNA analysis demonstrated a homozy-
gous absence of SMN1 exon 7, conﬁrming the diagnosis of
SMA. She had noticed no deﬁnite change in her strength in
the decade prior to her presentation to the SMA clinic. Her
examination revealed very slight levoscoliosis but no other
abnormalities. Her cranial nerves were normal. Peripheral
strength testing, performed with the use of the MedicalThe AmericanResearch Council (MRC) scale for muscle strength, re-
vealed grade 4 strength (normal being grade 5) in the
shoulder abductors, with grade 4þ elbow ﬂexors, grade 4
elbow extensors, and grade 5 or normal wrist extensors
and ﬂexors. In the legs, her hip ﬂexors, hip abductors,
and hip extensors were all grade 2 (not antigravity), with
grade 4 knee ﬂexors, grade 5 knee extensors, and grade 4
ankle dorsiﬂexors and evertors. Her gait was stable, with
signiﬁcant hyperlordosis. She was areﬂexic, with an other-
wise normal neurologic examination.
Dosage testing was performed in order to determine the
SMN2 copy number6 and revealed the absence of de-
tectable SMN2 exon 7. To our knowledge, the ﬁnding
(0 SMN1/0 SMN2 genotype) has never been reported in
SMA and was assumed to result in fetal demise, given
that there would be no protein produced from the SMN2
gene to protect the motor neurons. Because this genotype
was not consistent with the mild phenotype, we con-
cluded that the absence of SMN2 was most likely technical
in nature. Sequence variations have been shown to inhibit
primer binding during the PCR, and therefore a different
set of primers was utilized for both the sequencing of
SMN2 and the determination of SMN2 copy number. A
homozygous substitution of guanine by cytosine at nucle-
otide 859 (c.859G>C) was found in SMN2 exon 7 at the
þ25 position (Figure 1). This change replaces a glycine by
an arginine at codon 287 (p.G287R). This variant was ﬁrst
detected on a normal chromosome of an unaffected carrier
when it resulted in an abnormal single-strand conforma-
tion polymorphism (SSCP) pattern.21 This change was
also reported to affect the melting curve of a quantitative
real-time PCR assay based on the use of a speciﬁc hybridiza-
tion probe.8 The nucleotide change was shown to be local-
ized within the annealing region of the hybridized probe
assay and therefore altered the melting curve.
Dosage testing with a new set of primers showed that
the patient had two copies of SMN2, both positive for the
c.859G>C. A missense substitution of arginine for the
glycine is a signiﬁcant change in amino acid structure
and is predicted to alter the three-dimensional conforma-
tion of the SMN protein and may therefore result in
a less functional protein.22 However, Hua and Zhou found
that a random C-terminal tag of ﬁve or more amino acids
downstream of exon 6 was sufﬁcient to promote cyto-
plasmic localization of the SMND7.23 Wolstercroft et al.
demonstrated that the SMN exon 7 sequence is not specif-
ically required; rather, this region functions as a nonspe-
ciﬁc tail that facilitates proper localization.24 The authors
showed that a variety of native and synthetic C-terminal
amino acid sequences can restore wild-type SMN subcel-
lular localization patterns when fused to SMN exons 1–6.
Given that the majority of type I patients have two copies
of SMN2 and this patient presented with a mild type IIIb
phenotype, we hypothesized that the substitution not
only causes assay problems but may potentially be a posi-
tive modiﬁer. Although the C-to-T at þ6 in SMN2 exon 7
normally results in the production of SMN2 transcriptsJournal of Human Genetics 85, 408–413, September 11, 2009 409
Figure 1. SMN2 Sequence Analysis of
SMA Cases
The inclusion of exon 7 in SMN1 tran-
scripts, as well as the exclusion of this
exon in SMN2 transcripts, is caused by
the C-to-T change difference shown at
nucleotide position 6 in SMN2 exon 7.
The substitution of guanine by cytosine
at nucleotide 859 (c.859G>C) is shown at
nucleotide position 25 in SMN2 exon 7.
(A) Wild-type SMN2 sequence chromato-
gram.
(B) Case 1, showing a homozygous substi-
tution of guanine by cytosine at nucleo-
tide 859 (c.859G>C) at nucleotide posi-
tion 25.
(C) Case 2, showing a heterozygous substi-
tution of guanine by cytosine at nucleo-
tide 859 (c.859G>C) at nucleotide posi-
tion 25. The patient has one wild-type
SMN2 copy.
(D) Case 3, also showing the substitution
of guanine by cytosine at nucleotide
859 (c.859G>C) at nucleotide position
25. The patient has two wild-type SMN2
copies.predominantly lacking exon 7 (by disrupting an ESE or
creating an ESS), the c.859G>Cmay act to partially restore
normal exon splicing and produce more full-length SMN2
transcript; e.g., by creating a new ESE or disrupting an ESS.
ESEs are cis-acting elements that stimulate splicing and
are often required for efﬁcient intron removal, whereas
ESSs inhibit splicing. Many ESEs act as binding sites for
serine/arginine-rich proteins (SR proteins), a family of
essential splicing factors, and promote splicing by recruit-
ing spliceosomal components. Each SR protein recognizes
a distinct functional sequence motif. We used ESEﬁnder
3.0, which includes four motif matrices of SR proteins
(SF2/ASF, SC35, SRp40, and SRp55), to score wild-type
and mutant sequences (Figure 2).25,26 The c.859G>C spe-
ciﬁcally creates a new high-score SF2/ASF motif. As shown
in Figure 2, there is now a new SF/ASF2 motif with a score
of 3.50 created by the mutant sequence. The wild-type
score is 0.60, which is below the threshold, usually set at
1.88. We concluded that a SF2/ASF recognition sequence
created by the substitution may have allowed for increased
full-length transcript and thus resulted in a milder pheno-
type than predicted from the SMN2 copy number alone.
For further investigation of the functional signiﬁcance
of the new SF2/ASF motif, a transient transfection experi-
ment was performed as previously described.27 The
c.859G>C was introduced by site-directed mutagenesis
into an SMN2 minigene plasmid. The variant, SMN2, and
SMN1 minigene plasmids were separately electroporated
into human embryonic kidney (HEK) 293 cells, and RNA
was isolated from the cells 2 days later. After reverse tran-
scription, the variant, SMN1, and SMN2 cDNAs were ampli-410 The American Journal of Human Genetics 85, 408–413, Septemﬁed for 25 cycles in the presence of a-32P-dCTP, and the
labeled PCR products were separated on a 6% polyacryl-
amide gel, followed by phosphorimage analysis. The exon
7 inclusion level as a percentage of the total spliced mRNA
was determined. As shown in Figure 2, the c.859G>C
substitution showed a signiﬁcant increase of exon 7 inclu-
sion, to 70%, in comparison to an inclusion level of 50%
for the wild-type SMN2 minigene (n ¼ 3, p % 0.01). We
note that although the precise extent of exon 7 inclusion
differs between minigenes and intact genes, the greater
inclusion of the exon in SMN1 than in SMN2 is preserved.
In addition, changes in ratios of exon-included to exon-
skipped isoforms are accurately reﬂected in semiquantita-
tive, radioactive reverse transcriptase-PCR done in the
linear range of ampliﬁcation.14,27
There is another high-score SF2/ASF motif beginning at
position 33 of exon 7 in both SMN1 and SMN2, shown in
Figure 2A.28 However, this does not appear to be a func-
tional SF2/ASF element, given that mutating it in an
SMN1 minigene had no effect on exon 7 inclusion and
had little or no effect in the context of SMN2 (M.L. Hast-
ings, J.A. Calarco, and A.R.K, unpublished data). In addi-
tion, the motif may not be accessible to SF2/ASF, because
two nucleotides (AT) at its 30 end are part of an RNA
secondary structure element (TSL2) that promotes exon 7
skipping. It remains possible that the new motif created
by c.859G>C is recognized by SF2/ASF in conjunction
with the preexisting motif at position 33 of the exon.
Also of note, the new presumptive SF2/ASF motif begin-
ning at position 25 overlaps the Tra2b motif beginning at
position 22, and the nucleotide change would be expectedber 11, 2009
to weaken or disrupt the binding of this SR-like protein,
which recognizes a purine-rich motif.16 Because of the
overlap of the motifs, we do not expect that both proteins
could bind simultaneously, so perhaps a loss of Tra2b
binding is more than compensated for by a gain of SF2/
ASF binding. We have not ruled out the possibility that
a splicing activator other than SF2/ASF recognizes an
element created or strengthened by the mutation or that
the mutation disrupts the binding of a putative repressor
to a greater extent than it disrupts the binding of Tra2b.
Because the c.859G>C substitution was initially identi-
ﬁed in a type IIIb patient with only two SMN2 copies, we
decided to screen all of our discrepant cases, whereby the
SMN2 copy numbers predicted more severe disease pre-
sentations than observed. We had previously identiﬁed
another seven of these cases, and we now found the
same substitution in two additional unrelated patients in
this group.
The second case was a 31-year-old woman with SMA
type IIIa. Early motor milestones were normal (crawling
by 9 months, standing with support by 15 months,
Figure 2. c.859G>C Creates a Putative SF2/ASF Motif
(A) ESEﬁnder3.0, which includes four motif matrices of SR
proteins, SF2/ASF, SC35, SRp40, and SRp55, predicts a strong
SF2/ASF motif CGAAGGT with a score of 3.50 that was created
by c.859G>C. Note that the wild-type sequence GGAAGGT score
is 0.60 and the standard threshold is usually set at 1.88.
(B) c.859G>C in the context of the SMN2 minigene showed
a signiﬁcant increase of exon 7 inclusion during pre-mRNA
splicing in comparison to the wild-type SMN2 minigene.The Americanwalking independently by 18 months), but at 2–3 years
of age, her gait became unsteady and she preferred to
hold on to furniture while waking. She required assistance
in ambulation from 5–6 yrs of age and ultimately was
completely wheelchair dependent by age 12. She under-
went scoliosis surgery at 14 years of age. At the time of
her initial evaluation in the SMA clinic (at age 26), she
had good respiratory function and could minimally assist
with transfers, but she required full assistance for most
activities of daily living, including bathroom activities
and dressing. She could still sit unsupported, get from
a sitting position to a lying position, and partially roll.
She had signiﬁcant hip and knee contractures. She also
had signiﬁcant arm weakness, with 3 grade shoulder
abductors and elbow extensors and grade 4 wrist extensors
and ﬁnger extensors. She could not lift her arms to shoul-
der level, had moderate elbow contractures, and was
unable to fully extend her ﬁngers. She had grade 0 hip
and knee extensors. Deep tendon reﬂexes were absent.
DNA testing initially indicated that she had a 0 SMN1/1
SMN2 genotype, which was not consistent with her milder
type IIIa presentation. With utilization of the redesigned
SMN2 primers, dosage testing revealed a second copy of
SMN2, which was positive for the variant (Figure 1).
Because we have observed the 0 SMN1/2 SMN2 genotype
in 90% of our type I patients, this ﬁnding in case 2
provided additional support for a positive modifying effect
of the SMN2 change.
The third case was a 29-year-old male type IIIb patient
who had normal earlymotormilestones and development.
At approximately age 12, he was noted to have ‘‘skinny
legs’’ and began having trouble keeping up in gym class.
He had difﬁculty running while in high school, but did
not feel there was deﬁnitely something wrong until age
22, when he realized he was not gaining strength despite
an intensive weight lifting program. He sought medical
attention, and electrodiagnostic studies revealed chronic
neurogenic changes. DNA testing revealed a homozygous
deletion of SMN1 genes, and a diagnosis of SMA was
made. His medical history was otherwise remarkable only
for restless leg syndrome, slight depression, and mild
attention deﬁcit disorder. Examination at the time of
presentation to the SMA clinic revealed a normal general
examination and normal cranial nerves with no tongue
fasciculations. Peripherally, he had very mild proximal
upper extremity weakness, with grade 4 strength in the
shoulder abductors and 4þ strength in the elbow ﬂexors.
All other upper extremity groups were normal (i.e., grade
5). In the legs, his hip ﬂexors and knee extensors were
grade 2, knee ﬂexors were grade 4, and ankle dorsiﬂexors
and ankle everters were grade 5. His gait was slow but stable
with signiﬁcant genu recurvatum. He was areﬂexic, and
the rest of his neurologic examination was normal. DNA
testing initially indicated that he had a 0 SMN1/2 SMN2
genotype. Because we had not observed this genotype in
our type IIIb population, the patient was retested with
the new primer set, and he was shown to have a thirdJournal of Human Genetics 85, 408–413, September 11, 2009 411
copy of SMN2 with the c.859G>C. Although the majority
of our type III patients have three SMN2 copies, the milder
type IIIb patients often have four SMN2 copies. In our
previous studies of type III patients; 76% had three, 24%
had four, and 1% demonstrated ﬁve copies of the SMN2
gene.9
Because this mutation was detected in our discrepant
milder cases, we also screened 41 unselected type I patients,
and we did not identify themutation in any of the patients
with a more severe phenotype. We also tested a discordant
SMA family (SMA family 6), which included siblings who
were positive for the homozygous SMN1 deletion and had
the same SMN2 copy number but markedly different clin-
ical manifestations.29 The family had one daughter with
the type II phenotype anda sonwith amild type IIIbpresen-
tation, who was still ambulant at 20 years of age. Both
siblings were negative for the variant. Lastly, we tested
139 unaffected individuals, who were all previously shown
tohave 2 SMN1/2 SMN2 genotypes, and all of the 278 SMN2
alleles were negative for the c.859G>C.
In this report, we have shown a positive modifying effect
of the c.859G>C substitution in three milder cases of SMA,
in which the SMN2 copy number did not correlate with the
clinical phenotype. This change had been previously re-
ported and shown to cause methodological issues, which
we also observed. Upon further examination, however,
we now show that the change apparently creates a new
ESE site, increasing the amount of full-length transcript
and thus resulting in a milder phenotype than that pre-
dicted from the SMN2 copy number alone. Our study
suggests that the c.859G>C substitution is likely to be an
important modiﬁer accounting for some of the exception
patients, given that it has been observed by other investi-
gators and we have identiﬁed the substitution in three
unrelated discrepant cases, the ﬁrst of which had two
copies of the variant. Furthermore, there appears to be
a selective advantage in this change, given that we did
not observe it in any of our type I or unaffected individ-
uals. This is also true of the SMN2 copy number; elevated
SMN2 copies (>3) are rarely found in type I patients and
unaffected individuals. There are additional genes outside
the SMA region that modify the disease severity, as has
been demonstrated by rare cases with discordant siblings
with identical SMN2 copy numbers. However, it should
not be assumed that all SMN2 genes are equivalent, and
sequence changes found within the SMN2 gene should
be further investigated for potential positive or negative
effects on SMN2 transcription and posttranscriptional
RNA processing. Importantly, the cases presented here
also support a potential therapeutic beneﬁt in increasing
the SMN2 gene expression in order to decrease the severity
of the disorder.
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